<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4181714</article-id><article-id pub-id-type="pmid">25239601</article-id><article-id pub-id-type="publisher-id">4877</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-685</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Integrated genomic study of quadruple-WT GIST (<italic>KIT/PDGFRA/SDH/RAS</italic> pathway wild-type GIST)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nannini</surname><given-names>Margherita</given-names></name><address><email>margherita.nannini@unibo.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Astolfi</surname><given-names>Annalisa</given-names></name><address><email>annalisa.astolfi@unibo.it</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Urbini</surname><given-names>Milena</given-names></name><address><email>milena.urbini@yahoo.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Indio</surname><given-names>Valentina</given-names></name><address><email>valentina.indio2@unibo.it</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Santini</surname><given-names>Donatella</given-names></name><address><email>donatella.santini@aosp.bo.it</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Heinrich</surname><given-names>Michael C</given-names></name><address><email>heinrich@ohsu.edu</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Corless</surname><given-names>Christopher L</given-names></name><address><email>corlessc@ohsu.edu</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Ceccarelli</surname><given-names>Claudio</given-names></name><address><email>claudio.ceccarelli@unibo.it</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Saponara</surname><given-names>Maristella</given-names></name><address><email>maristellasaponara@yahoo.it</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Mandrioli</surname><given-names>Anna</given-names></name><address><email>anna.mandrioli@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Lolli</surname><given-names>Cristian</given-names></name><address><email>crilolli@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ercolani</surname><given-names>Giorgio</given-names></name><address><email>giorgio.ercolani@unibo.it</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Brandi</surname><given-names>Giovanni</given-names></name><address><email>giovanni.brandi@unibo.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Biasco</surname><given-names>Guido</given-names></name><address><email>guido.biasco@unibo.it</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Pantaleo</surname><given-names>Maria A</given-names></name><address><email>maria.pantaleo@unibo.it</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Department of Specialized, Experimental and Diagnostic Medicine, Sant&#x02019;Orsola-Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy </aff><aff id="Aff2"><label/>&#x0201c;Giorgio Prodi&#x0201d; Cancer Research Center, University of Bologna, Bologna, Italy </aff><aff id="Aff3"><label/>Pathology Unit, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy </aff><aff id="Aff4"><label/>Portland VA Medical Center and Knight Cancer Institute, and Division of Hematology and Oncology, Oregon Health &#x00026; Science University Portland, Portland, OR USA </aff><aff id="Aff5"><label/>Department of Pathology and Knight Cancer Institute, Oregon Health &#x00026; Science University, Portland, OR USA </aff><aff id="Aff6"><label/>Transplant, General and Emergency Surgery Department, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>685</elocation-id><history><date date-type="received"><day>23</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Nannini et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>About 10-15% of adult gastrointestinal stromal tumors (GIST) and the vast majority of pediatric GIST do not harbour <italic>KIT</italic> or platelet-derived growth factor receptor alpha (<italic>PDGFRA</italic>) mutations (J Clin Oncol 22:3813&#x02013;3825, 2004; Hematol Oncol Clin North Am 23:15&#x02013;34, 2009). The molecular biology of these GIST, originally defined as <italic>KIT/PDGFRA</italic> wild-type (WT), is complex due to the existence of different subgroups with distinct molecular hallmarks, including defects in the succinate dehydrogenase (<italic>SDH</italic>) complex and mutations of neurofibromatosis type 1 (<italic>NF1</italic>), <italic>BRAF</italic>, or <italic>KRAS</italic> genes (<italic>RAS</italic>-pathway or <italic>RAS-P</italic>).</p><p>In this extremely heterogeneous landscape, the clinical profile and molecular abnormalities of the small subgroup of WT GIST suitably referred to as <italic>quadruple wild-type</italic> GIST (<italic>quadruple</italic><sup>WT</sup> or <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup>) remains undefined. The aim of this study is to investigate the genomic profile of <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup> GIST, by using a massively parallel sequencing and microarray approach, and compare it with the genomic profile of other GIST subtypes.</p></sec><sec><title>Methods</title><p>We performed a whole genome analysis using a massively parallel sequencing approach on a total of 16 GIST cases (2 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup> and <italic>SDHB</italic><sup>IHC+</sup>/<italic>SDHA</italic><sup>IHC+</sup>, 2 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> and <italic>SDHB</italic><sup>IHC-</sup>/<italic>SDHA</italic><sup>IHC-</sup> and 12 cases of <italic>KIT</italic><sup>mut</sup> or <italic>PDGFRA</italic><sup>mut</sup> GIST). To confirm and extend the results, whole-genome gene expression analysis by microarray was performed on 9 out 16 patients analyzed by RNAseq and an additional 20 GIST patients (1 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup><italic>SDHA</italic><sup>mut</sup> GIST and 19 <italic>KIT</italic><sup>mut</sup> or <italic>PDGFRA</italic><sup>mut</sup> GIST). The most impressive data were validated by quantitave PCR and Western Blot analysis.</p></sec><sec><title>Results</title><p>We found that both cases of <italic>quadruple</italic><sup>WT</sup> GIST had a genomic profile profoundly different from both either <italic>KIT/PDGFRA</italic> mutated or <italic>SDHA</italic>-mutated GIST. In particular, the <italic>quadruple</italic><sup>WT</sup> GIST tumors are characterized by the overexpression of molecular markers (<italic>CALCRL</italic> and <italic>COL22A1</italic>) and of specific oncogenes including tyrosine and cyclin- dependent kinases (<italic>NTRK2</italic> and <italic>CDK6</italic>) and one member of the <italic>ETS</italic>-transcription factor family (<italic>ERG</italic>).</p></sec><sec><title>Conclusion</title><p>We report for the first time an integrated genomic picture of <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup> GIST, using massively parallel sequencing and gene expression analyses, and found that <italic>quadruple</italic><sup>WT</sup> GIST have an expression signature that is distinct from <italic>SDH</italic>-mutant GIST as well as GIST harbouring mutations in <italic>KIT</italic> or <italic>PDGFRA</italic>. Our findings suggest that <italic>quadruple</italic><sup>WT</sup> GIST represent another unique group within the family of gastrointestintal stromal tumors.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/1471-2407-14-685) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Gastrointestinal stromal tumors (GIST)</kwd><kwd>Wild-type</kwd><kwd><italic>KIT</italic></kwd><kwd><italic>PDGFRA</italic></kwd><kwd>Succinate dehydrogenase</kwd><kwd><italic>SDHA</italic></kwd><kwd><italic>RAS</italic></kwd><kwd><italic>Quadruple</italic><sup>WT</sup></kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>About 10-15% of adult gastrointestinal stromal tumors (GIST) and the vast majority of pediatric GIST do not harbour <italic>KIT</italic> or platelet-derived growth factor receptor alpha (<italic>PDGFRA</italic>) mutations [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. These GIST were originally defined as <italic>KIT/PDGFRA</italic> wild-type (<italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>) and generally are less sensitive to tyrosine-kinase inhibitors [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. Their molecular biology is heterogeneous as evidence by the existence of different subgroups with distinct molecular abnormalities (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> GIST can be divided into two main groups according to the succinate dehydrogenase subunit B (SDHB) immunohistochemical status (IHC): <italic>SDHB</italic> positive (<italic>SDHB</italic><sup>IHC+</sup>), or <italic>type 1</italic> GIST which, includes neurofibromatosis type 1 (<italic>NF1</italic>)-mutated GIST and some sporadic <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> GIST. The second group of <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>, called as <italic>type 2</italic> GIST, is characterized by a lack of <italic>SDHB</italic> protein expression (<italic>SDHB</italic><sup>IHC-</sup>). In some cases <italic>SDHB</italic><sup>IHC-</sup> is due to germline and/or <italic>de novo</italic> mutations of any of the four <italic>SDH</italic> subunits (<italic>SDHA</italic><sup>mut</sup>) [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. The <italic>SDHB</italic><sup>IHC-</sup> includes additional subgroups that can be distinguished on the basis of the <italic>SDHA</italic> IHC status, which strictly correlates with the presence of <italic>SDHA</italic>-inactivating mutations (<italic>SDHA</italic><sup>mut</sup>) [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. In particular, <italic>SDHB</italic><sup>IHC-</sup>/<italic>SDHA</italic><sup>IHC-</sup> GIST include a subgroup of young adult women patients with a well defined clinical and biological profile, generally characterized by the gastric primary tumour localization, a predominantly mixed epithelioid and spindle cell morphology, diffuse IHC positivity for <italic>KIT</italic> and discovered on gastrointestinal stromal tumours 1 (<italic>DOG1</italic>), frequent lymph node metastases, and an indolent course of disease even if metastasis is present [<xref ref-type="bibr" rid="CR17">17</xref>]. Moreover, they are characterized by overexpression of the insulin growth factor 1 receptor (<italic>IGF1R</italic>) [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. On the contrary, <italic>SDHB</italic><sup>IHC-</sup>, but <italic>SDHA</italic><sup>IHC+</sup> subgroup include 1) cases of syndromic GIST arising from the Carney-Stratakis Syndrome (CSS), that are characterized by <italic>SDHB</italic>, <italic>SDHC</italic> or <italic>SDHD</italic> inactivating mutations (<italic>SDHB</italic><sup>mut</sup>, <italic>SDHC</italic><sup>mut</sup>, or <italic>SDHD</italic><sup>mut</sup>); and 2) cases of Carney Triad (CT), that lack <italic>SDH</italic>x-mutations [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. More rarely, <italic>SDHB</italic><sup>IHC-</sup>/<italic>SDHA</italic><sup>IHC+</sup> subgroup may include sporadic <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> GIST characterized by <italic>SDHB</italic>, &#x02212;<italic>C</italic> or <italic>D</italic> mutations (most of them germline, and in few cases by <italic>SDHA</italic> mutations), arising mainly from the stomach, with a lesser female prevalence, but histologically similar to <italic>SDHA</italic><sup>IHC-</sup> GIST [<xref ref-type="bibr" rid="CR15">15</xref>].<fig id="Fig1"><label>Figure 1</label><caption><p><bold>The complexity of</bold>
<bold><italic>KIT</italic></bold>
<sup><bold>WT</bold></sup>
<bold>/</bold>
<bold><italic>PDGFRA</italic></bold>
<sup><bold>WT</bold></sup>
<bold>GIST molecular biology.</bold>
<italic>KIT</italic>
<sup>WT</sup>/<italic>PDGFRA</italic>
<sup>WT</sup> GIST could be firstly divided two main group according to the <italic>SDHB</italic> immunohistochemical status: <italic>SDHB</italic>
<sup>IHC+</sup> (including <italic>NF1</italic>-mutated GIST and sporadic <italic>KIT</italic>
<sup>WT</sup>/<italic>PDGFRA</italic>
<sup>WT</sup> GIST with or without <italic>KRAS/BRAF</italic> mutations) and <italic>SDHB</italic>
<sup>IHC-</sup> or <italic>SDH-deficient</italic> GIST. The latter could be further divided according to the SDHA immunohistochemical status: <italic>SDHB</italic>
<sup>IHC-</sup>/<italic>SDHA</italic>
<sup>IHC-</sup> GIST (pediatric type or young adult GIST characterized by germline or somatic inactivating <italic>SDHA</italic> mutations) and <italic>SDHB</italic>
<sup>IHC</sup>/<italic>SDHA</italic>
<sup>IHC+</sup> GIST (including Carney-Stratakis Syndrome-related GIST, characterized by germline or somatic inactivating <italic>SDHB</italic>, &#x02212;<italic>C</italic>, &#x02212;<italic>D</italic> mutations, Carney Triad-related GIST that lack <italic>SDHx</italic> mutations, and sporadic <italic>KIT</italic>
<sup>WT</sup>/<italic>PDGFRA</italic>
<sup>WT</sup> GIST, characterized by germline or somatic inactivating <italic>SDHB</italic>, &#x02212;<italic>C</italic>, &#x02212;<italic>D</italic> mutations and <italic>SDHA</italic> mutations, reported in only three cases [<xref ref-type="bibr" rid="CR15">15</xref>]. In red the subset of <italic>KIT</italic>
<sup>WT</sup>/<italic>PDGFRA</italic>
<sup>WT</sup> GIST referred to as <italic>quadruple</italic>
<sup>WT</sup> GIST (<italic>KIT</italic>
<sup>WT</sup>/<italic>PDGFRA</italic>
<sup>WT</sup>/<italic>SDH</italic>
<sup>WT</sup>/<italic>RAS-P</italic>
<sup>WT</sup>), that represent the subject of this study.</p></caption><graphic xlink:href="12885_2014_4877_Fig1_HTML" id="d30e1219"/></fig></p><p>The <italic>SDHB</italic><sup>IHC+</sup> subgroup includes cases of <italic>NF1</italic>-mutated GIST, that are commonly intestinal, multifocal and have an <italic>IGF1R</italic> negative staining, and also sporadic <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> GIST, arising in the adult from any part of gastrointestinal tract [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. In about 15% of cases of sporadic <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> GIST there may be an activating mutation in <italic>BRAF</italic> or, more rarely, <italic>RAS</italic>
[<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>]. Taken together, cases of <italic>BRAF</italic>, <italic>RAS</italic>, or <italic>NF1</italic> mutant GIST can be referred to as <italic>RAS</italic>-pathway (<italic>RAS-P</italic>) mutant GIST (<italic>RAS-P</italic><sup>mut</sup>).</p><p>In this extremely heterogeneous landscape, the clinical profile and molecular abnormalities of the small subgroup of WT GIST suitably referred to as <italic>quadruple wild-type</italic> GIST (<italic>quadruple</italic><sup>WT</sup> or <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup>) remains undefined [<xref ref-type="bibr" rid="CR29">29</xref>]. The aim of this study is to investigate the genomic profile of <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup> GIST, by using a massively parallel sequencing and microarray approach, and compare it with the genomic profile of other GIST subtypes.</p></sec><sec id="Sec2"><title>Results and discussion</title><sec id="Sec3"><title>Whole-Transcriptome Paired-End RNA Sequencing and copy number analysis</title><p>Whole-Transcriptome Paired-End RNA Sequencing was performed on a total of 16 GIST samples, of which 2 were <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> without <italic>SDH</italic>-inactivating mutations and <italic>SDHB</italic><sup>IHC+</sup>/<italic>SDHA</italic><sup>IHC+</sup> (GIST_133 and GIST_127), 2 were <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> and <italic>SDHB</italic><sup>IHC-</sup>/<italic>SDHA</italic><sup>IHC-</sup> (GIST_7 and GIST_10), and 12 were <italic>KIT</italic><sup>mut</sup> or <italic>PDGFRA</italic><sup>mut</sup>. The principal component analysis showed that both GIST_133 and GIST_127 (<italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup> and <italic>SDHB</italic><sup>IHC+</sup>/<italic>SDHA</italic><sup>IHC+</sup>) are characterized by a gene expression profile profoundly different from both GIST_7 and GIST_10 (<italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> and <italic>SDHB</italic><sup>IHC</sup>/<italic>SDHA</italic><sup>IHC</sup>), while clustering in proximity of a subset of <italic>KIT</italic><sup>mut</sup> or <italic>PDGFRA</italic><sup>mut</sup> GIST (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Principal Component Analysis (PCA) performed on samples analyzed with RNA-seq (Figure</bold>
2
<bold>A) and microarray (Figure</bold>
2
<bold>B).</bold> In both cases the patients with <italic>SDHA</italic> mutations are arranged in a strongly separated cluster (yellow points), as were the <italic>KIT</italic>
<sup>WT</sup>/<italic>PDGFRA</italic>
<sup>WT</sup>/<italic>SDH</italic>
<sup>WT</sup>/<italic>RAS-P</italic>
<sup>WT</sup> samples (red point) although closer to <italic>KIT</italic> or <italic>PDGFRA</italic> mutated (respectively blue and green point).</p></caption><graphic xlink:href="12885_2014_4877_Fig2_HTML" id="d30e1546"/></fig></p><p>To investigate the presence of novel mutations or small ins/del in the whole coding regions of <italic>KIT</italic> and PDGFRA we analyzed whole transcriptome sequencing data for single nucleotide variant (SNV) and found no private or cryptic mutations. Moreover, no <italic>NF-1</italic>, <italic>BRAF</italic>, <italic>RAS</italic> mutations were found by whole transcriptome sequencing. Therefore, the GIST from these two patients were <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup>, or <italic>quadruple</italic><sup>WT</sup> GIST. Analysis of deleterious mutations from whole transcriptome sequencing did not identify any known oncogenic event or shared alteration in the two patients (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). Copy number analysis was performed on the two <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup> GIST: GIST_133 showed no genomic imbalances, while GIST_127 harbors several macroscopic cytogenetic alterations, including loss of chromosome arms 14q and 22q frequently observed in <italic>KIT/PDGFRA</italic> mutated GIST.</p></sec><sec id="Sec4"><title>Gene expression analysis</title><p>To confirm and extend the results, whole-genome gene expression analysis by microarray was performed on 9 out 16 patients analyzed by RNAseq and an additional 20 GIST patients (1 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup><italic>SDHA</italic><sup>mut</sup> GIST and 19 <italic>KIT</italic><sup>mut</sup> or <italic>PDGFRA</italic><sup>mut</sup> GIST). The principal component analysis confirmed that both <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup> GIST have a genetic profile significantly different from all three <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> GIST, and cluster in close proximity to some <italic>KIT</italic><sup>mut</sup> GIST samples (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). Supervised gene expression analysis revealed the presence of specific genetic signatures characterizing the different molecular subgroups of GIST (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>); the <italic>SDHA</italic><sup>mut</sup> group showed a gene signature mainly characterized by the over-expression of <italic>IGF1R</italic> (p value 2.7X10<sup>&#x02212;11</sup>) and of neural markers (<italic>LHX2</italic>, <italic>KIRREL3</italic>) [<xref ref-type="bibr" rid="CR30">30</xref>], whereas as expected, all <italic>PDGFRA</italic><sup>mut</sup> GIST were clearly separated from <italic>KIT</italic><sup>mut</sup> GIST, especially for the expression of <italic>PDGFRA</italic>.<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Representation of top-scoring genes significantly over-expressed in the four GIST classes, (</bold>
<bold><italic>KIT</italic></bold>
<sup><bold>WT</bold></sup>
<bold>/</bold>
<bold><italic>PDGFRA</italic></bold>
<sup><bold>WT</bold></sup>
<bold>/</bold>
<bold><italic>SDH</italic></bold>
<sup><bold>WT</bold></sup>
<bold>/</bold>
<bold><italic>RAS-P</italic></bold>
<sup><bold>WT</bold></sup>
<bold>,</bold>
<bold><italic>SDHA</italic></bold>
<sup><bold>mut</bold></sup>
<bold>,</bold>
<bold><italic>KIT</italic></bold>
<sup><bold>mut</bold></sup>
<bold>and</bold>
<bold><italic>PDGFRA</italic></bold>
<sup><bold>mut</bold></sup>
<bold>), when each of them is compared with all other cases together.</bold>
</p></caption><graphic xlink:href="12885_2014_4877_Fig3_HTML" id="d30e1812"/></fig></p><p>The <italic>quadruple</italic><sup>WT</sup> (<italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup>) samples were characterized by a distinct gene expression profile (Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>), with 65 genes over-expressed or under-expressed (p value &#x0003c;&#x02009;0.005) compared with all the other GIST molecular subgroups. GSEA analysis of the transcriptional profile of <italic>quadruple</italic><sup>WT</sup> tumors showed enrichment of Polycomb target genes with respect to <italic>SDHA</italic><sup>mut</sup> GIST, in particular of the classes of PRC2 targets (p value 0.043) and H3K27-bound genes (p value 0.021). The function of the upregulated genes was related to cell cycle progression and MAPK signaling, ad exemplified by increased expression of SKP2, CDK6, FGF4, NTRK2). The <italic>quadruple</italic><sup>WT</sup> GIST tumors are characterized by the overexpression of molecular markers (<italic>CALCRL</italic> and <italic>COL22A1</italic>) and of specific oncogenes including tyrosine and cyclin- dependent kinases (<italic>NTRK2</italic> and <italic>CDK6</italic>) and one member of the <italic>ETS</italic>-transcription factor family (<italic>ERG</italic>). Overexpression of <italic>CALCRL</italic>, <italic>COL22A1</italic>, <italic>NTRK2</italic> (<italic>TrkB</italic>) and of the <italic>ETS</italic>-transcription factor <italic>ERG</italic> was confirmed by quantitative PCR, showing that only the <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup> GIST subgroup expressed these molecular markers and possible therapeutic targets (Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). <italic>NTRK2</italic> protein expression level was also evaluated by Western Blot analysis and its overexpression in <italic>quadruple</italic><sup>WT</sup> GIST was confirmed (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S1). No mutations, gene fusions or amplifications were identified in <italic>NTRK2</italic> and <italic>ERG</italic>.<fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Unsupervised hierarchical clustering representation of differential expressed genes (P-value &#x0003c;&#x02009;0.005) in</bold>
<bold><italic>KIT</italic></bold>
<sup><bold>WT</bold></sup>
<bold>/</bold>
<bold><italic>PDGFRA</italic></bold>
<sup><bold>WT</bold></sup>
<bold>/</bold>
<bold><italic>SDH</italic></bold>
<sup><bold>WT</bold></sup>
<bold>/</bold>
<bold><italic>RAS-P</italic></bold>
<sup><bold>WT</bold></sup>
<bold>GIST with respect to the other GIST classes (</bold>
<bold><italic>SDHx</italic></bold>
<sup><bold>mut</bold></sup>
<bold>,</bold>
<bold><italic>KIT</italic></bold>
<sup><bold>mut</bold></sup>
<bold>and</bold>
<bold><italic>PDGFRA</italic></bold>
<sup><bold>mut</bold></sup>
<bold>).</bold>
</p></caption><graphic xlink:href="12885_2014_4877_Fig4_HTML" id="d30e2024"/></fig><fig id="Fig5"><label>Figure 5</label><caption><p>
<bold>Quantitative PCR estimation of</bold>
<bold><italic>ERG</italic></bold>
<bold>,</bold>
<bold><italic>NTRK2</italic></bold>
<bold>,</bold>
<bold><italic>CALCRL</italic></bold>
<bold>and</bold>
<bold><italic>COL22A1</italic></bold>
<bold>expression in GIST.</bold> Relative expression of <italic>ERG</italic> (upper left panel), <italic>NTRK2</italic> (upper right panel), <italic>CALCRL</italic> (lower left panel) and <italic>COL22A1</italic> (lower right panel) mRNA in the two <italic>KIT</italic>
<sup>WT</sup>/<italic>PDGFRA</italic>
<sup>WT</sup>/<italic>SDH</italic>
<sup>WT</sup>/<italic>RAS-P</italic>
<sup>WT</sup> GIST in respect to the others molecular subgroups (4 <italic>SDHx</italic>
<sup>mut</sup>, 19 <italic>KIT</italic>
<sup>mut</sup> and 10 <italic>PDGFRA</italic>
<sup>mut</sup> GIST). Significance was estimated by the Student T-test: *p-value &#x0003c;&#x02009;0.05; **p-value &#x0003c;&#x02009;0.01; ***p-value &#x0003c;&#x02009;0.001.</p></caption><graphic xlink:href="12885_2014_4877_Fig5_HTML" id="d30e2118"/></fig></p></sec></sec><sec id="Sec5" sec-type="discussion"><title>Discussion</title><p>The pathogenesis and underlying biology of <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> with intact <italic>SDH</italic> complex (<italic>SDHx</italic><sup>WT</sup>) and non-mutated <italic>RAS</italic>-pathway members (<italic>RAS-P</italic><sup>WT</sup>) suitably referred to as <italic>quadruple</italic><sup>WT</sup> GIST remains undefined. In the present study, we performed a whole genome analysis using a massively parallel sequencing approach on a total of 16 GIST cases that included 2 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup> and <italic>SDHB</italic><sup>IHC+</sup>/<italic>SDHA</italic><sup>IHC+,</sup>, 2 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> and <italic>SDHB</italic><sup>IHC-</sup>/<italic>SDHA</italic><sup>IHC-</sup> and 12 cases of <italic>KIT</italic><sup>mut</sup> or <italic>PDGFRA</italic><sup>mut</sup> GIST. Notably, we found that both cases of <italic>quadruple</italic><sup>WT</sup> GIST had a transcriptome profile profoundly different from both <italic>KIT/PDGFRA</italic> mutated and <italic>SDHA</italic>-mutated GIST, suggesting a different molecular background underlying <italic>quadruple</italic><sup>WT</sup> GIST. Since both cases of <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup> lacked mutations of <italic>BRAF</italic>, <italic>RAS</italic> family members or <italic>NF1</italic>, the GIST of these two patients was classified <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup> or <italic>quadruple</italic><sup>WT</sup> GIST. We further validated our data using genome wide gene expression analysis, performed on 9 cases from a previous series that was expanded to include an additional 20 GIST cases (1 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> GIST and 19 <italic>KIT</italic><sup>mut</sup> or <italic>PDGFRA</italic><sup>mut</sup> GIST). This larger analysis confirmed the unique gene expression signature of the two <italic>quadruple</italic><sup>WT</sup> GIST compared to KIT mutant, PDGFRA mutant or SDHA-mutant GIST. Interestingly, the gene signatures of the <italic>quadruple</italic><sup>WT</sup> GIST, which both arose in the small intestine, clustered in close proximity to a single <italic>KIT</italic><sup>mut</sup> GIST sample (GIST_13). This case was a small intestine GIST of intermediate risk of relapse radically resected from a 46&#x000a0;year old; it harbored an exon 11 <italic>KIT</italic> point mutation (<italic>KIT</italic> exon 11 V559D). Our current sample size does not allow us to draw definitive conclusions, but we hypothesize that the intestinal origin of all three tumors may have influenced the gene signature. However, several other cases of small intestinal origin did not cluster near the cases of <italic>quadruple</italic><sup>WT</sup> GIST. The influence of the tissue of origin on the gene signature is consistent with the recent data by Beadling <italic>et al</italic>., who described five cluster groups among 136 GIST patients (53 <italic>KIT</italic><sup>mut</sup>, 12 <italic>PDGFRA</italic><sup>mut</sup>, 65 adult <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> and 7 pediatric <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>) defined by the expression patterns of 14 target genes, that were in some cases paralleled by the location of the primary tumour [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p>Using a supervised analysis, we found four gene cluster subgroups based on <italic>KIT/PDGFRA/SDH</italic>-mutational status. Due to the rarity of <italic>RAS-P</italic> mutated GIST, we did not have any cases suitable for these genomic studies. Consistent with previous reports, <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> GIST over-expressed <italic>IGF1R</italic>, further confirming the potential role of this receptor as a target or diagnostic marker for this specific molecular subgroup [<xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Moreover, as already described, the gene signature of <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> GIST was largely characterized by the expression of neural-commitment transcription markers, in support of the theory that this subgroup may have a different cellular origin or may derive from interstitial cells of Cajal (ICCs) during a different differentiation step, such as from precursors of ICCs [<xref ref-type="bibr" rid="CR30">30</xref>]. Notably, both <italic>quadruple</italic><sup>WT</sup> GIST had a distinct gene expression signature that was separated from the <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> GIST. Amongst the differentially expressed genes, it is interesting to note the over-expression of <italic>CALCRL</italic>, a G protein-coupled receptor that acts as a receptor for adrenomedullin and calcitonin gene-related peptide (<italic>CGRP</italic>), and is strongly expressed by in several vascular tumours and types of gliomas [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>]. Also of interest, we found over-expression of <italic>COL22A1</italic>, a member of the collagen protein family which specifically localizes to tissue junctions and acts as a cell adhesion ligand for skin epithelial cells and fibroblasts [<xref ref-type="bibr" rid="CR36">36</xref>]. Taken together, these findings may suggest the potential role of <italic>CALCRL</italic> and <italic>COL22A1</italic> as diagnostic markers for the identification of this GIST subgroup. This would need to be validated in a larger series of GIST.</p><p>We found that both <italic>quadruple</italic><sup>WT</sup> GIST, in comparison with the other samples, strongly expressed several oncogenes, including <italic>ERG</italic> and <italic>NTRK2</italic> (<italic>TrkB</italic>). This was confirmed by quantitative PCR. <italic>ERG</italic> is a well-known member of the erythroblast transformation-specific (<italic>ETS</italic>) family of transcription factors, which function as transcriptional regulators [<xref ref-type="bibr" rid="CR37">37</xref>]. <italic>ETS</italic> proteins are regulated by the mitogenic (<italic>RAS/MAPK</italic>) signalling transduction pathway, and play an important role in cell differentiation, proliferation, apoptosis and tissue remodelling [<xref ref-type="bibr" rid="CR38">38</xref>]. There is evidence for an oncogenic role of <italic>ERG</italic> and the other <italic>ETS</italic> transcription factors in many human cancers, including sarcomas, prostate cancer, and acute myeloid leukemia, in most cases via chromosomal translocations [<xref ref-type="bibr" rid="CR39">39</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>]. More recently, it has been shown that the IHC detection of <italic>ERG</italic> may be a useful marker for vascular tumors, prostate carcinoma and <italic>ERG</italic>-rearranged Ewing sarcoma [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. Over-expression of <italic>NTRK2</italic> (<italic>TrkB</italic>) in <italic>quadruple</italic><sup>WT</sup> GIST is also of interest, as <italic>NTRK2</italic> helps regulated neuronal cell function, including synaptic plasticity, differentiation, growth, survival, and motility [<xref ref-type="bibr" rid="CR45">45</xref>]. It has also been shown that <italic>Trks</italic> regulate important processes in non-neuronal cells, contributing to the pathogenesis of several kinds of cancer, such as medullary thyroid carcinoma, prostate cancer, non-small cell lung cancer, head and neck squamous cell carcinoma and pancreatic cancer, in addition to tumors of neural origin [<xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>]. Given the relevant biological role played by <italic>Trks</italic> in cancer, different small molecule inhibitors have been developed and evaluated both in mono-therapy and in combination with chemotherapy in phase 1 and 2 clinical trials [<xref ref-type="bibr" rid="CR52">52</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref>].</p><p>To our knowledge, the over-expression of <italic>ERG</italic> and <italic>TrkB</italic> in GIST has not been previously reported. However, it is well known that <italic>ETV1</italic>, another member of <italic>ETS</italic> family, is highly expressed in GIST and certain subsets of ICC. <italic>ETV1</italic> expression plays an important role in regulating the growth of <italic>KIT</italic> mutant GIST cell lines [<xref ref-type="bibr" rid="CR59">59</xref>]. On the basis of our results, the overexpression of <italic>ERG</italic> and <italic>TrkB</italic> seems to be a unique feature of the <italic>quadruple</italic><sup>WT</sup> GIST, suggesting that it could play a relevant role in the pathogenesis of this subset of GIST. To translate these observations into clinical practice, the over-expression of both molecules could be investigated as diagnostic markers of <italic>quadruple</italic><sup>WT</sup> GIST.</p></sec><sec id="Sec6" sec-type="conclusions"><title>Conclusions</title><p>In conclusion, we report for the first time an integrated genomic picture of the <italic>quadruple</italic><sup>WT</sup> GIST, using massively parallel sequencing and gene expression analyses, and have identified a unique subset of GIST among the family of the KIT/PDGFRA WT GIST [<xref ref-type="bibr" rid="CR60">60</xref>]. The frequency of this GIST subset amongst the family of GIST will need to be defined in future studies as well as any unique clinical-pathological features of this GIST subset, including response to conventional GIST medical therapy. In addition, ongoing studies of ICC developmental biology may help identify the &#x0201c;normal&#x0201d; precursor cells that give rise to this unique GIST subgroup.</p></sec><sec id="Sec7" sec-type="methods"><title>Methods</title><p>This study was approved by the institutional review board of Azienda Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi, Bologna, Italy (approval number 113/2008/U/Tess). All patients provided written informed consent.</p><sec id="Sec8"><title>Patients and tumor samples</title><p>Fresh tissue specimens of GIST from 36 patients were collected during the surgical operation, snap-frozen in liquid nitrogen and stored at &#x02212;80&#x000b0;C until analysis. Patient&#x02019;s characteristics are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Patient&#x02019;s characteristic</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>ID</th><th>Sex</th><th>Array</th><th>RNAseq</th><th>Age</th><th>Site</th><th>Disease status at diagnosis</th><th>
<bold><italic>KIT/PDGFRA/SDH</italic></bold>mutational status</th></tr></thead><tbody><tr><td>
<bold>GIST_133</bold>
</td><td>M</td><td>X</td><td>X</td><td>57</td><td>Duodenum</td><td>Localized</td><td>WT</td></tr><tr><td>
<bold>GIST_127</bold>
</td><td>F</td><td>X</td><td>X</td><td>63</td><td>Ileum</td><td>Localized</td><td>WT</td></tr><tr><td>
<bold>GIST_07</bold>
</td><td>F</td><td>X</td><td>X</td><td>27</td><td>Stomach</td><td>Metastatic</td><td>
<italic>SDHA</italic> exon 9 p.S384X</td></tr><tr><td rowspan="2">
<bold>GIST_10</bold>
</td><td rowspan="2">M</td><td rowspan="2">X</td><td rowspan="2">X</td><td rowspan="2">29</td><td rowspan="2">Stomach</td><td rowspan="2">Metastatic</td><td>
<italic>SDHA</italic> exon 2 p.R31X;</td></tr><tr><td>
<italic>SDHA</italic> exon 13 p.R589W</td></tr><tr><td>
<bold>GIST_188</bold>
</td><td>F</td><td/><td>X</td><td>57</td><td>Duodenum</td><td>Metastatic</td><td>
<italic>KIT</italic> exon 11 p.N564-L576 del&#x02009;+&#x02009;<italic>KIT</italic> exon 17 p.N822K</td></tr><tr><td>
<bold>GIST_174</bold>
</td><td>M</td><td/><td>X</td><td>59</td><td>Stomach</td><td>Metastatic</td><td>
<italic>KIT</italic> exon 11 p.N564_L576 del&#x02009;+&#x02009;<italic>KIT</italic> exon 17 p.N822K</td></tr><tr><td>
<bold>GIST_131</bold>
</td><td>M</td><td>X</td><td>X</td><td>58</td><td>Ileum</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.V569_Y578 del</td></tr><tr><td>
<bold>GIST_11</bold>
</td><td>M</td><td>X</td><td>X</td><td>65</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.557-558 del</td></tr><tr><td>
<bold>GIST_134</bold>
</td><td>F</td><td>X</td><td>X</td><td>65</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon p.V559D</td></tr><tr><td>
<bold>GIST_124</bold>
</td><td>M</td><td>X</td><td>X</td><td>70</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.1765-1766 ins</td></tr><tr><td>
<bold>GIST_150</bold>
</td><td>F</td><td/><td>X</td><td>55</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.P551_E554 del</td></tr><tr><td>
<bold>GIST_165</bold>
</td><td>M</td><td/><td>X</td><td>50</td><td>Stomach</td><td>Localized</td><td>
<italic>PDGFRA</italic> exon 18 p.D842V</td></tr><tr><td>
<bold>GIST_136</bold>
</td><td>M</td><td>X</td><td>X</td><td>76</td><td>Stomach</td><td>Localized</td><td>
<italic>PDGFRA</italic> exon 18 p.D842V</td></tr><tr><td>
<bold>GIST_140</bold>
</td><td>F</td><td/><td>X</td><td>45</td><td>Stomach</td><td>Localized</td><td>
<italic>PDGFRA</italic> exon 18 p.D842V</td></tr><tr><td>
<bold>GIST_141</bold>
</td><td>M</td><td/><td>X</td><td>68</td><td>Stomach</td><td>Localized</td><td>
<italic>PDGFRA</italic> exon 18 p.D842V</td></tr><tr><td>
<bold>GIST_138</bold>
</td><td>F</td><td/><td>X</td><td>75</td><td>Stomach</td><td>Localized</td><td>
<italic>PDGFRA</italic> exon 18 p.D842V</td></tr><tr><td>
<bold>GIST_02</bold>
</td><td>F</td><td>X</td><td/><td>85</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.V560D</td></tr><tr><td>
<bold>GIST_04</bold>
</td><td>M</td><td>X</td><td/><td>79</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 9 p.AY502-503 ins</td></tr><tr><td>
<bold>GIST_05</bold>
</td><td>M</td><td>X</td><td/><td>68</td><td>Stomach</td><td>Localized</td><td>
<italic>PDGFRA</italic> exon 12 p.SPDGHE566-571RIQ</td></tr><tr><td>
<bold>GIST_08</bold>
</td><td>M</td><td>X</td><td/><td>62</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.V559D</td></tr><tr><td>
<bold>GIST_09</bold>
</td><td>M</td><td>X</td><td/><td>54</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 TLQPYDHKWEEFP 574&#x02013;585 ins at P585</td></tr><tr><td>
<bold>GIST_12</bold>
</td><td>F</td><td>X</td><td/><td>66</td><td>Stomach</td><td>Localized</td><td>
<italic>PDGFRA</italic> exon 14 p.K646E</td></tr><tr><td>
<bold>GIST_13</bold>
</td><td>M</td><td>X</td><td/><td>46</td><td>Small intestine</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.V559D</td></tr><tr><td>
<bold>GIST_14</bold>
</td><td>M</td><td>X</td><td/><td>56</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.WK557-558del</td></tr><tr><td>
<bold>GIST_15</bold>
</td><td>F</td><td>X</td><td/><td>64</td><td>Stomach</td><td>Localized</td><td>
<italic>PDGFRA</italic> exon 18 DIMH p.842-845 DIMH del</td></tr><tr><td>
<bold>GIST_16</bold>
</td><td>F</td><td>X</td><td/><td>62</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.L576P</td></tr><tr><td>
<bold>GIST_20</bold>
</td><td>M</td><td>X</td><td/><td>38</td><td>Small intestine</td><td>Metastatic</td><td>
<italic>KIT</italic> exon 11 del MYEQW552-557 Z&#x02009;+&#x02009;<italic>KIT</italic> exon 18 A829P</td></tr><tr><td>
<bold>GIST_22</bold>
</td><td>F</td><td>X</td><td/><td>76</td><td>Stomach</td><td>NA</td><td>
<italic>PDGFRA</italic> exon 18 p.D842V</td></tr><tr><td>
<bold>GIST_23</bold>
</td><td>F</td><td>X</td><td/><td>47</td><td>Stomach</td><td>NA</td><td>
<italic>KIT</italic> exon 11 p.V559D</td></tr><tr><td>
<bold>GIST_24</bold>
</td><td>F</td><td>X</td><td/><td>18</td><td>Stomach</td><td>Metastatic</td><td>
<italic>SDHA</italic> exon 8 p.L349R fs*11</td></tr><tr><td>
<bold>GIST_26</bold>
</td><td>M</td><td>X</td><td/><td>49</td><td>Stomach</td><td>Localized</td><td>
<italic>PDGFRA</italic> exon 12 p.V561D</td></tr><tr><td>
<bold>GIST_121</bold>
</td><td>M</td><td>X</td><td/><td>71</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.V559D</td></tr><tr><td>
<bold>GIST_125</bold>
</td><td>F</td><td>X</td><td/><td>48</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.W557R</td></tr><tr><td>
<bold>GIST_129</bold>
</td><td>M</td><td>X</td><td/><td>59</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon11 p.Y553_V559 delins L</td></tr><tr><td>
<bold>GIST_130</bold>
</td><td>F</td><td>X</td><td/><td>79</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 9 p.A502-Y503 ins</td></tr><tr><td>
<bold>GIST_135</bold>
</td><td>F</td><td>X</td><td/><td>61</td><td>Stomach</td><td>Localized</td><td>
<italic>KIT</italic> exon 11 p.W557-E561 del</td></tr></tbody></table></table-wrap></p><p>Whole-Transcriptome Paired-End RNA Sequencing was performed on 16 GIST, including 2 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> GIST patients without <italic>SDH</italic>-inactivating mutations (GIST_133 and GIST_127), 2 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> GIST patients harbouring <italic>SDHA</italic>-mutations (GIST_7 and GIST_10), and 12 <italic>KIT</italic> or <italic>PDGFRA</italic> mutated GIST patients (7 harboured exon 11 <italic>KIT</italic> mutations and 5 harboured exon 18 <italic>PDGFRA</italic> mutations).</p><p>Whole-genome gene expression analysis was performed on 9 of the above 16 GIST and extended to include an additional 20 GIST: 1 <italic>KIT</italic><sup><italic>W</italic>T</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDHA</italic><sup>mut</sup> GIST and 19 <italic>KIT</italic> or <italic>PDGFRA</italic> mutated GIST, of which 13 harboured <italic>KIT</italic> mutations (12 in exon 11 and 2 in exon 9), and 5 harboured <italic>PDGFRA</italic> mutations (2 in exon 12, 1 in exon 14 and 2 in exon 18).</p></sec><sec id="Sec9"><title>SDH status</title><p><italic>SDH</italic> protein expression status was evaluated by both immunohistochemistry (IHC) of <italic>SDHB</italic> and <italic>SDH</italic> subunits sequencing. IHC was performed on 4-&#x003bc;m sections of FFPE GIST tumor samples. Rabbit polyclonal anti-<italic>SDHB</italic> (HPA002868, Sigma-Aldrich, St Louis, MO, USA, 1:800) antibody was used. The sections were deparaffinized, rehydrated, and subjected to the appropriate antigen retrieval treatment (<italic>SDHB</italic>: microwave heating in citrate buffer pH&#x000a0;6.0 at 100 1C for 40&#x000a0;min). After cooling at room temperature, the activity of endogenous peroxidises was inhibited using methanol/H2O2 (0.5%&#x000a0;v/v) for 20&#x000a0;min. The sections were then washed in phosphate-buffered saline (PBS, pH&#x000a0;7.2&#x02013;7.4) and incubated with the specific primary antibody overnight at room temperature. After that, the sections were washed in PBS and treated using the Novolink Polymer Detection System (Novocastra, Newcastle upon Tyne, UK) according to the manufacturer&#x02019;s instructions. Liver tissues (for <italic>SDHB</italic>) were used as positive controls. These tissues showed strong granular staining in the cytoplasm and mitochondria with both of the antibodies.</p><p><italic>SDHA</italic> gene exons [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>], <italic>SDHB</italic> gene exons [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], <italic>SDHC</italic> (exon 1&#x02013;6) and <italic>SDHD</italic> (exon 1&#x02013;4) were sequenced on fresh-frozen tumor specimens of <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup> GIST patients by Sanger Sequencing method. DNA was extracted by the QIAmp DNA Mini kit (Qiagen, Milan, Italy) in accordance with manufacturer&#x02019;s directions. Each exon was amplified with Polymerase Chain Reaction (PCR) amplification using specific primer pairs designed with Primer Express 3.0 Software (Applied Biosystem) to amplify exons but not <italic>SDHA</italic> pseudo-genes located on chromosomes 3 and 5. Then, PCR products were purified with the Qiaquick PCR purification kit (Qiagen, Milan, Italy) and sequenced on both strands using the Big Dye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems). Sanger sequencing was performed on ABI 3730 Genetic Analyzer (Applied Biosystems).</p></sec><sec id="Sec10"><title>Whole-transcriptome paired-end RNA sequencing</title><p>Total RNA was extracted from tumor specimens with RNeasy Mini Kit (Qiagen, Milan, Italy), then cDNA libraries were synthesized from 250&#x000a0;ng total RNA with TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, CA) according to the manufacturer&#x02019;s recommendations. Sequencing by synthesis was performed on HiScanSQ sequencer (Illumina) at 75&#x000a0;bp in paired-end mode. Whole-transcriptome sequencing yielded an average of 61 million mapped reads/patient, thus reaching an average coverage of 44X. Two <italic>SDHA</italic><sup>mut</sup> tumor specimens were previously analyzed by whole transcriptome sequencing at the Genome Sciences Centre (Vancouver, Canada) [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec11"><title>Bioinformatic analysis</title><p>After demultiplexing and FASTQ generation (both steps performed with Casava1.8, an application software specifically developed by Illumina), the paired-end reads quality were analyzed with the function fastx_quality_stats (part of FASTX Toolkit available at <ext-link ext-link-type="uri" xlink:href="http://hannonlab.cshl.edu/fastx_toolkit/index.html">http://hannonlab.cshl.edu/fastx_toolkit/index.html</ext-link>). Based on these results we decided to trim each read of each sample at 74&#x000a0;bp in order to maximize sequence quality. The paired-end reads were mapped with the pipeline TopHat/Bowtie [<xref ref-type="bibr" rid="CR61">61</xref>] on human reference genome HG19, collected from UCSC Genome Browser (<ext-link ext-link-type="uri" xlink:href="http://www.genome.ucsc.edu/">http://www.genome.ucsc.edu/</ext-link>). After the alignment procedure the BAM file obtained was manipulated with Samtools [<xref ref-type="bibr" rid="CR62">62</xref>] in order to remove the optical/PCR duplicate, to sort and to index it.</p><p>The analysis of gene expression was performed in two steps: 1) the function htseq-count (Python package HTseq) [<xref ref-type="bibr" rid="CR63">63</xref>] was adopted to count the number of reads mapped on known genes, included in the Ensembl release 72 annotation features (<ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org">http://www.ensembl.org</ext-link>); 2) the differential expressed genes were evaluated using the R-Bioconductor package edger [<xref ref-type="bibr" rid="CR64">64</xref>]. DeFuse, ChimeraScan and FusionMap packages were used to detect chimeric transcripts from RNA-seq data.</p></sec><sec id="Sec12"><title>Gene expression analysis</title><p>RNA was extracted using RNeasy Mini Kit (Qiagen), quality-controlled and labeled as directed by the Affymetrix expression technical manual before hybridization to U133Plus 2.0 arrays. Gene expression data were quantified by the RMA algorithm, filtered and analyzed with supervised techniques by Limma modified t-test for the detection of differentially expressed genes. Differential expressed genes hierarchical clustering and Principal Component Analysis (PCA) were performed with Multiple Array Viewer (MEV available at <ext-link ext-link-type="uri" xlink:href="http://www.tm4.org/mev.html">http://www.tm4.org/mev.html</ext-link>). The same software was used to represent the data in the Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> and Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. Gene expression data of <italic>KIT/PDGFRA</italic>-mutated and <italic>SDHA</italic>-mutated samples were previously reported [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec13"><title>Copy number analysis</title><p>Genomic DNA was labelled and hybridized to SNP array Genome Wide SNP 6.0 (Affymetrix) following manufacturer&#x02019;s instructions. Quality control was performed by Contrast QC and MAPD calculation. Copy number analysis was performed by Genotyping Console and visualized with Chromosome Analysis Suite (<italic>ChAS</italic>) Software (Affymetrix). Hidden Markov Model algorithm was used to detect amplified and deleted segments with stringent parameters. To control for hyperfragmentation adjacent segments separated by &#x0003c;&#x02009;50 probes were combined into one single segment, and only segments &#x0003e;&#x02009;100 probes were considered.</p></sec><sec id="Sec14"><title>Quantitative PCR (qPCR)</title><p>Total RNA was reverse transcribed using Transcriptor First Strand cDNA synthesis kit (Roche Applied Science, Monza, Italy) with oligo-dT primers, according to the manufacturer&#x02019;s guidelines. Gene-specific primers were designed with Primer Express 3.0 Software (Applied Biosystems) and qPCR was performed using FastStart Sybr Green (Roche) on the LightCycler 480 apparatus (Roche). DDCt method was used to quantify gene product levels relative to the GAPDH and ATP5B housekeeping genes. Significance was estimated by the Student&#x02019;s <italic>t</italic> test: * p-value &#x0003c;&#x02009;0.05; ** p-value &#x0003c;&#x02009;0.01, *** p-value &#x0003c;&#x02009;0.01.</p></sec><sec id="Sec15"><title>Western blot</title><p>Protein expression of <italic>NTRK2</italic> was evaluated on 2 <italic>KIT</italic><sup>WT</sup>/<italic>PDGFRA</italic><sup>WT</sup>/<italic>SDH</italic><sup>WT</sup>/<italic>RAS-P</italic><sup>WT</sup> GIST and 8 <italic>KIT</italic> or <italic>PDGFRA</italic> or <italic>SDH</italic> mutant GISTs, of which fresh-frozen tissues were available. Tissue were disrupted in RIPA buffer (Sigma-Aldrich) supplemented with proteases inhibitors and lysed for 1&#x000a0;h with gentle agitation at 4&#x000b0;C. Lysates were centrifuged at 13,000 &#x000d7; <italic>g</italic> for 15&#x000a0;min at 4&#x000b0;C and supernatants were stored at &#x02212;80&#x000b0;C. Protein concentrations were determined with the BCA protein assay (Pierce, Rockford, IL). Twenty micrograms of protein were resolved on a 8% SDS-PAGE gel and transferred onto polyvinylidene difluoride (PVDF) membranes. Nonspecific binding sites were blocked by incubation in blocking buffer (PBS containing 0.1% Tween-20 with 5%&#x000a0;w/v milk) for 1&#x000a0;h at room temperature. Membranes were incubated overnight at 4&#x000b0;C, with the following primary antibodies: rabbit polyclonal <italic>TRKB</italic> antibody (ab18987 Abcam 1:500), and rabbit polyclonal &#x003b2;-<italic>Tubulin</italic> antibody (sc-9104 Santa Cruz Biotechnology, Santa Cruz, CA, 1:500). Then, membranes were washed and incubated with peroxidase conjugate secondary antibodies for 1&#x000a0;h at room temperature. Antigens were revealed using Enhanced Chemiluminescence Reaction (ECL Select, Amersham Pharmacia Biotech, Les Ulis, France).</p></sec></sec><sec id="Sec16"><title>Nomenclature</title><p><italic>KIT</italic><sup>WT</sup> No mutations of <italic>KIT</italic></p><p><italic>PDGFRA</italic><sup>WT</sup> No mutations of <italic>PDGFRA</italic></p><p><italic>SDH</italic><sup>WT</sup> No abnormalities of <italic>SDHA/B/C/D</italic> protein expression and/or gene mutation</p><p><italic>SDHA</italic><sup>IHC &#x02013;</sup> No expression of <italic>SDHA</italic> protein</p><p><italic>SDHA</italic><sup>IHC +</sup> Normal expression of <italic>SDHA</italic> protein</p><p><italic>SDHB</italic><sup>IHC &#x02013;</sup> No expression of <italic>SDHB</italic> protein</p><p><italic>SDHB</italic><sup>IHC +</sup> Normal expression of <italic>SDHB</italic> protein</p><p><italic>SDHA</italic><sup>mut</sup> Mutation of <italic>SDHA</italic> protein (homozygous or compound heterozygote)</p><p><italic>SDHB</italic><sup>mut</sup> Mutation of <italic>SDHB</italic> protein (homozygous or compound heterozygote)</p><p><italic>SDHC</italic><sup>mut</sup> Mutation of <italic>SDHC</italic> protein (homozygous or compound heterozygote)</p><p><italic>SDHD</italic><sup>mut &#x02013;</sup> Mutation of <italic>SDHD</italic> protein (homozygous or compound heterozygote)</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec17"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12885_2014_4877_MOESM1_ESM.xlsx"><caption><p>Additional file 1: Table S1:
<italic>NTRK2</italic> protein overexpression in <italic>KIT</italic>
<sup>WT</sup>/<italic>PDGFRA</italic>
<sup>WT</sup>/<italic>SDH</italic>
<sup>WT</sup>/<italic>RAS-P</italic>
<sup>WT</sup> GIST. Western blot immunostaining of <italic>NTRK2</italic> was perfomed on proteins extracted from two <italic>quadruple</italic>
<sup>WT</sup> GIST and from eight <italic>PDGFRA</italic> or <italic>KIT</italic> or <italic>SDH</italic> mutated GIST. HL-60 cell line protein extract was used as positive control. (XLSX 18 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12885_2014_4877_MOESM2_ESM.docx"><caption><p>Additional file 2: Figure S1:
<italic>NTRK2</italic> protein overexpression in <italic>KIT</italic>
<sup>WT</sup>/<italic>PDGFRA</italic>
<sup>WT</sup>/<italic>SDH</italic>
<sup>WT</sup>/<italic>RAS-P</italic>
<sup>WT</sup> GIST. Western blot immunostaining of <italic>NTRK2</italic> was perfomed on proteins extracted from two <italic>quadruple</italic>
<sup>WT</sup> GIST and from eight <italic>PDGFRA</italic> or <italic>KIT</italic> or <italic>SDH</italic> mutated GIST. HL-60 cell line protein extract was used as positive control. (DOCX 159 KB)</p></caption></media></supplementary-material></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term><italic>CGRP</italic></term><def><p>Calcitonin gene-related peptide</p></def></def-item><def-item><term>CSS</term><def><p>Carney-Stratakis Syndrome</p></def></def-item><def-item><term>CT</term><def><p>Carney Triad</p></def></def-item><def-item><term><italic>DOG1</italic></term><def><p>Discovered on gastrointestinal stromal tumours 1</p></def></def-item><def-item><term><italic>ETS</italic></term><def><p>Erythroblast transformation-specific</p></def></def-item><def-item><term>GIST</term><def><p>Gastrointestinal stromal tumors</p></def></def-item><def-item><term>ICCs</term><def><p>Cells of Cajal</p></def></def-item><def-item><term><italic>IGF1R</italic></term><def><p>Insulin growth factor 1 receptor</p></def></def-item><def-item><term>IHC</term><def><p>Immunohistochemistry</p></def></def-item><def-item><term><italic>NF1</italic></term><def><p>Neurofibromatosis type 1</p></def></def-item><def-item><term><italic>PDGFRA</italic></term><def><p>Platelet-derived growth factor receptor alpha</p></def></def-item><def-item><term><italic>RAS</italic>-P</term><def><p>RAS-pathway</p></def></def-item><def-item><term><italic>SDH</italic></term><def><p>Succinate dehydrogenase</p></def></def-item><def-item><term>SNV</term><def><p>Single nucleotide variant</p></def></def-item><def-item><term>WT</term><def><p>Wild-type.</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>MN: have made substantial contributions to conception and design of the study, interpretation of data and drafted the manuscript; AA: carried out the molecular genetic studies, the sequence alignment and have been involved in drafting the manuscript. MU: carried out the molecular genetic studies, the sequence alignment and have been involved in drafting the manuscript. VI: carried out the bioinformatic analysis and interpretation of data and have been involved in drafting the manuscript. DS: carried out the pathological analysis and the collection of samples. MCH: have been involved in revising the manuscript critically for important intellectual content and have given final approval of the version to be published. CLC: have been involved in revising the manuscript critically for important intellectual content and have given final approval of the version to be published. MS, AM and CL have helped to draft and revised the manuscript. GE: carried out the surgical collection of samples. GB: have been involved in revising the manuscript critically for important intellectual content and have given final approval of the version to be published. MAP: have made substantial contributions to conception and design of the study, interpretation of data and drafted the manuscript; All authors read and approved the final manuscript.</p></fn></fn-group><ack><p>All staff of Bologna GIST Study Group: Annalisa Altimari, Claudio Ceccarelli, Paolo Castellucci, Fausto Catena, Monica Di Battista, Massimo Del Gaudio, Valerio Di Scioscio, Stefano Fanti, Michelangelo Fiorentino, Pietro Fusaroli, Lidia Gatto, Franco W. Grigioni, Elisa Gruppioni, Alessandra Maleddu, Maria Caterina Pallotti, Antonio Daniele Pinna, Paola Tommasetti, Maurizio Zompatori.</p><p>
<bold>Funding</bold>
</p><p>The present work was done with a financial contribution by Novartis Oncology, Italy, and with funds by My First Grant 2013, AIRC 2013.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corless</surname><given-names>CL</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name></person-group><article-title>Biology of gastrointestinal stromal tumors</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>3813</fpage><lpage>3825</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.05.140</pub-id><?supplied-pmid 15365079?><pub-id pub-id-type="pmid">15365079</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janeway</surname><given-names>KA</given-names></name><name><surname>Pappo</surname><given-names>AS</given-names></name></person-group><article-title>Pediatric gastrointestinal stromal tumor</article-title><source>Hematol Oncol Clin North Am</source><year>2009</year><volume>23</volume><fpage>15</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2008.11.005</pub-id><?supplied-pmid 19248968?><pub-id pub-id-type="pmid">19248968</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Corless</surname><given-names>CL</given-names></name><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>Blanke</surname><given-names>CD</given-names></name><name><surname>von Mehren</surname><given-names>M</given-names></name><name><surname>Joensuu</surname><given-names>H</given-names></name><name><surname>McGreevey</surname><given-names>LS</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Van den Abbeele</surname><given-names>AD</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Kiese</surname><given-names>B</given-names></name><name><surname>Eisenberg</surname><given-names>B</given-names></name><name><surname>Roberts</surname><given-names>PJ</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Silberman</surname><given-names>S</given-names></name><name><surname>Dimitrijevic</surname><given-names>S</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name></person-group><article-title>Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>4342</fpage><lpage>4349</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.04.190</pub-id><?supplied-pmid 14645423?><pub-id pub-id-type="pmid">14645423</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debiec-Rychter</surname><given-names>M</given-names></name><name><surname>Sciot</surname><given-names>R</given-names></name><name><surname>Le Cesne</surname><given-names>A</given-names></name><name><surname>Schlemmer</surname><given-names>M</given-names></name><name><surname>Hohenberger</surname><given-names>P</given-names></name><name><surname>van Oosterom</surname><given-names>AT</given-names></name><name><surname>Blay</surname><given-names>JY</given-names></name><name><surname>Leyvraz</surname><given-names>S</given-names></name><name><surname>Stul</surname><given-names>M</given-names></name><name><surname>Casali</surname><given-names>PG</given-names></name><name><surname>Zalcberg</surname><given-names>J</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Van Glabbeke</surname><given-names>M</given-names></name><name><surname>Hagemeijer</surname><given-names>A</given-names></name><name><surname>Judson</surname><given-names>I</given-names></name><collab>EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group</collab></person-group><article-title>KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours</article-title><source>Eur J Cancer</source><year>2006</year><volume>42</volume><fpage>1093</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2006.01.030</pub-id><?supplied-pmid 16624552?><pub-id pub-id-type="pmid">16624552</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Owzar</surname><given-names>K</given-names></name><name><surname>Corless</surname><given-names>CL</given-names></name><name><surname>Hollis</surname><given-names>D</given-names></name><name><surname>Borden</surname><given-names>EC</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Ryan</surname><given-names>CW</given-names></name><name><surname>von Mehren</surname><given-names>M</given-names></name><name><surname>Blanke</surname><given-names>CD</given-names></name><name><surname>Rankin</surname><given-names>C</given-names></name><name><surname>Benjamin</surname><given-names>RS</given-names></name><name><surname>Bramwell</surname><given-names>VH</given-names></name><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>Bertagnolli</surname><given-names>MM</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name></person-group><article-title>Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>5360</fpage><lpage>5367</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.17.4284</pub-id><?supplied-pmid 18955451?><pub-id pub-id-type="pmid">18955451</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>AJ</given-names></name><name><surname>Chou</surname><given-names>A</given-names></name><name><surname>Vilain</surname><given-names>R</given-names></name><name><surname>Clarkson</surname><given-names>A</given-names></name><name><surname>Lui</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Tobias</surname><given-names>V</given-names></name><name><surname>Samra</surname><given-names>J</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Sioson</surname><given-names>L</given-names></name><name><surname>Parker</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>RC</given-names></name><name><surname>Sywak</surname><given-names>M</given-names></name><name><surname>Sidhu</surname><given-names>SB</given-names></name><name><surname>Wyatt</surname><given-names>JM</given-names></name><name><surname>Robinson</surname><given-names>BG</given-names></name><name><surname>Eckstein</surname><given-names>RP</given-names></name><name><surname>Benn</surname><given-names>DE</given-names></name><name><surname>Clifton-Bligh</surname><given-names>RJ</given-names></name></person-group><article-title>Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types</article-title><source>Am J Surg Pathol</source><year>2010</year><volume>34</volume><fpage>636</fpage><lpage>644</lpage><?supplied-pmid 20305538?><pub-id pub-id-type="pmid">20305538</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>ZF</given-names></name><name><surname>Sarlomo-Rikala</surname><given-names>M</given-names></name><name><surname>Osuch</surname><given-names>C</given-names></name><name><surname>Rutkowski</surname><given-names>P</given-names></name><name><surname>Lasota</surname><given-names>J</given-names></name></person-group><article-title>Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age</article-title><source>Am J Surg Pathol</source><year>2011</year><volume>35</volume><fpage>1712</fpage><lpage>1721</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e3182260752</pub-id><?supplied-pmid 21997692?><pub-id pub-id-type="pmid">21997692</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janeway</surname><given-names>KA</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Lodish</surname><given-names>M</given-names></name><name><surname>Nos&#x000e9;</surname><given-names>V</given-names></name><name><surname>Rustin</surname><given-names>P</given-names></name><name><surname>Gaal</surname><given-names>J</given-names></name><name><surname>Dahia</surname><given-names>PL</given-names></name><name><surname>Liegl</surname><given-names>B</given-names></name><name><surname>Ball</surname><given-names>ER</given-names></name><name><surname>Raygada</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>AH</given-names></name><name><surname>Kelly</surname><given-names>L</given-names></name><name><surname>Hornick</surname><given-names>JL</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>M</given-names></name><name><surname>de Krijger</surname><given-names>RR</given-names></name><name><surname>Dinjens</surname><given-names>WN</given-names></name><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name><name><surname>Helman</surname><given-names>L</given-names></name><name><surname>Stratakis</surname><given-names>CA</given-names></name><collab>NIH Pediatric and Wild-Type GIST Clinic</collab></person-group><article-title>Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>314</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1073/pnas.1009199108</pub-id><?supplied-pmid 21173220?><pub-id pub-id-type="pmid">21173220</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantaleo</surname><given-names>MA</given-names></name><name><surname>Astolfi</surname><given-names>A</given-names></name><name><surname>Indio</surname><given-names>V</given-names></name><name><surname>Moore</surname><given-names>R</given-names></name><name><surname>Thiessen</surname><given-names>N</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Gnocchi</surname><given-names>C</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Catena</surname><given-names>F</given-names></name><name><surname>Formica</surname><given-names>S</given-names></name><name><surname>Martelli</surname><given-names>PL</given-names></name><name><surname>Casadio</surname><given-names>R</given-names></name><name><surname>Pession</surname><given-names>A</given-names></name><name><surname>Biasco</surname><given-names>G</given-names></name></person-group><article-title>SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing</article-title><source>J Natl Cancer Inst</source><year>2011</year><volume>103</volume><fpage>983</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr130</pub-id><?supplied-pmid 21505157?><pub-id pub-id-type="pmid">21505157</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantaleo</surname><given-names>MA</given-names></name><name><surname>Nannini</surname><given-names>M</given-names></name><name><surname>Astolfi</surname><given-names>A</given-names></name><name><surname>Biasco</surname><given-names>G</given-names></name><collab>GIST Study Group Bologna</collab></person-group><article-title>A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations</article-title><source>Am J Surg Pathol</source><year>2011</year><volume>35</volume><fpage>1750</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e318230a523</pub-id><?supplied-pmid 21997697?><pub-id pub-id-type="pmid">21997697</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Italiano</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>CL</given-names></name><name><surname>Sung</surname><given-names>YS</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>DeMatteo</surname><given-names>RP</given-names></name><name><surname>LaQuaglia</surname><given-names>MP</given-names></name><name><surname>Besmer</surname><given-names>P</given-names></name><name><surname>Socci</surname><given-names>N</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name></person-group><article-title>SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors</article-title><source>BMC Cancer</source><year>2012</year><volume>12</volume><fpage>408</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-12-408</pub-id><?supplied-pmid 22974104?><pub-id pub-id-type="pmid">22974104</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>AJ</given-names></name><name><surname>Remillard</surname><given-names>SP</given-names></name><name><surname>Zhang</surname><given-names>YX</given-names></name><name><surname>Doyle</surname><given-names>LA</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Hornick</surname><given-names>JL</given-names></name></person-group><article-title>Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumors</article-title><source>Mod Pathol</source><year>2013</year><volume>26</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2012.153</pub-id><?supplied-pmid 22955521?><pub-id pub-id-type="pmid">22955521</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwight</surname><given-names>T</given-names></name><name><surname>Benn</surname><given-names>DE</given-names></name><name><surname>Clarkson</surname><given-names>A</given-names></name><name><surname>Vilain</surname><given-names>R</given-names></name><name><surname>Lipton</surname><given-names>L</given-names></name><name><surname>Robinson</surname><given-names>BG</given-names></name><name><surname>Clifton-Bligh</surname><given-names>RJ</given-names></name><name><surname>Gill</surname><given-names>AJ</given-names></name></person-group><article-title>Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors</article-title><source>Am J Surg Pathol</source><year>2013</year><volume>37</volume><fpage>226</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e3182671155</pub-id><?supplied-pmid 23060355?><pub-id pub-id-type="pmid">23060355</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oudijk</surname><given-names>L</given-names></name><name><surname>Gaal</surname><given-names>J</given-names></name><name><surname>Korpershoek</surname><given-names>E</given-names></name><name><surname>van Nederveen</surname><given-names>FH</given-names></name><name><surname>Kelly</surname><given-names>L</given-names></name><name><surname>Schiavon</surname><given-names>G</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><name><surname>Mathijssen</surname><given-names>RH</given-names></name><name><surname>den Bakker</surname><given-names>MA</given-names></name><name><surname>Oldenburg</surname><given-names>RA</given-names></name><name><surname>van Loon</surname><given-names>RL</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>MJ</given-names></name><name><surname>de Krijger</surname><given-names>RR</given-names></name><name><surname>Dinjens</surname><given-names>WN</given-names></name></person-group><article-title>SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors</article-title><source>Mod Pathol</source><year>2013</year><volume>26</volume><fpage>456</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2012.186</pub-id><?supplied-pmid 23174939?><pub-id pub-id-type="pmid">23174939</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>M</given-names></name><name><surname>Killian</surname><given-names>JK</given-names></name><name><surname>Wang</surname><given-names>ZF</given-names></name><name><surname>Lasota</surname><given-names>J</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Walker</surname><given-names>R</given-names></name><name><surname>Pineda</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Helman</surname><given-names>L</given-names></name><name><surname>Meltzer</surname><given-names>P</given-names></name></person-group><article-title>Immunohistochemical loss of succinate dehydrogenase subunit A (SDHA) in gastrointestinal stromal tumors (GISTs) signals SDHA germline mutation</article-title><source>Am J Surg Pathol</source><year>2013</year><volume>37</volume><fpage>234</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e3182671178</pub-id><?supplied-pmid 23282968?><pub-id pub-id-type="pmid">23282968</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pantaleo</surname><given-names>MA</given-names></name><name><surname>Astolfi</surname><given-names>A</given-names></name><name><surname>Urbini</surname><given-names>M</given-names></name><name><surname>Nannini</surname><given-names>M</given-names></name><name><surname>Paterini</surname><given-names>P</given-names></name><name><surname>Indio</surname><given-names>V</given-names></name><name><surname>Saponara</surname><given-names>M</given-names></name><name><surname>Formica</surname><given-names>S</given-names></name><name><surname>Ceccarelli</surname><given-names>C</given-names></name><name><surname>Casadio</surname><given-names>R</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Bertolini</surname><given-names>F</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Pirini</surname><given-names>MG</given-names></name><name><surname>Fiorentino</surname><given-names>M</given-names></name><name><surname>Basso</surname><given-names>U</given-names></name><name><surname>Biasco</surname><given-names>G</given-names></name><collab>on behalf of GIST Study Group, University of Bologna, Bologna, Italy</collab></person-group><article-title>Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST</article-title><source>Eur J Hum Genet</source><year>2013</year></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rege</surname><given-names>TA</given-names></name><name><surname>Wagner</surname><given-names>AJ</given-names></name><name><surname>Corless</surname><given-names>CL</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Hornick</surname><given-names>JL</given-names></name></person-group><article-title>&#x0201c;Pediatric-type&#x0201d; gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior</article-title><source>Am J Surg Pathol</source><year>2011</year><volume>35</volume><fpage>495</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e31820e5f7d</pub-id><?supplied-pmid 21358303?><pub-id pub-id-type="pmid">21358303</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Clarkson</surname><given-names>A</given-names></name><name><surname>Samra</surname><given-names>JS</given-names></name><name><surname>Clifton-Bligh</surname><given-names>RJ</given-names></name><name><surname>Hugh</surname><given-names>TJ</given-names></name><name><surname>Gill</surname><given-names>AJ</given-names></name></person-group><article-title>Succinate dehydrogenase-deficient GISTs are characterized by IGF1R overexpression</article-title><source>Mod Pathol</source><year>2012</year><volume>25</volume><fpage>1307</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2012.77</pub-id><?supplied-pmid 22555179?><pub-id pub-id-type="pmid">22555179</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nannini</surname><given-names>M</given-names></name><name><surname>Astolfi</surname><given-names>A</given-names></name><name><surname>Paterini</surname><given-names>P</given-names></name><name><surname>Urbini</surname><given-names>M</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Catena</surname><given-names>F</given-names></name><name><surname>Indio</surname><given-names>V</given-names></name><name><surname>Casadio</surname><given-names>R</given-names></name><name><surname>Pinna</surname><given-names>AD</given-names></name><name><surname>Biasco</surname><given-names>G</given-names></name><name><surname>Pantaleo</surname><given-names>MA</given-names></name></person-group><article-title>Expression of IGF-1 receptor in KIT/PDGF receptor-&#x003b1; wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction</article-title><source>Future Oncol</source><year>2013</year><volume>9</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.2217/fon.12.170</pub-id><?supplied-pmid 23252569?><pub-id pub-id-type="pmid">23252569</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belinsky</surname><given-names>MG</given-names></name><name><surname>Rink</surname><given-names>L</given-names></name><name><surname>Flieder</surname><given-names>DB</given-names></name><name><surname>Jahromi</surname><given-names>MS</given-names></name><name><surname>Schiffman</surname><given-names>JD</given-names></name><name><surname>Godwin</surname><given-names>AK</given-names></name><name><surname>Mehren</surname><given-names>M</given-names></name></person-group><article-title>Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors</article-title><source>Genes Chromosomes Cancer</source><year>2013</year><volume>52</volume><fpage>214</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1002/gcc.22023</pub-id><?supplied-pmid 23109135?><pub-id pub-id-type="pmid">23109135</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasota</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Helman</surname><given-names>L</given-names></name><name><surname>Miettinen</surname><given-names>M</given-names></name></person-group><article-title>Expression of the receptor for type I insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications</article-title><source>Am J Surg Pathol</source><year>2013</year><volume>37</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e3182613c86</pub-id><?supplied-pmid 22892600?><pub-id pub-id-type="pmid">22892600</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McWhinney</surname><given-names>SR</given-names></name><name><surname>Pasini</surname><given-names>B</given-names></name><name><surname>Stratakis</surname><given-names>CA</given-names></name></person-group><article-title>Familial gastrointestinal stromal tumors and germ-line mutations</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>1054</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1056/NEJMc071191</pub-id><?supplied-pmid 17804857?><pub-id pub-id-type="pmid">17804857</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasini</surname><given-names>B</given-names></name><name><surname>McWhinney</surname><given-names>SR</given-names></name><name><surname>Bei</surname><given-names>T</given-names></name><name><surname>Matyakhina</surname><given-names>L</given-names></name><name><surname>Stergiopoulos</surname><given-names>S</given-names></name><name><surname>Muchow</surname><given-names>M</given-names></name><name><surname>Boikos</surname><given-names>SA</given-names></name><name><surname>Ferrando</surname><given-names>B</given-names></name><name><surname>Pacak</surname><given-names>K</given-names></name><name><surname>Assie</surname><given-names>G</given-names></name><name><surname>Baudin</surname><given-names>E</given-names></name><name><surname>Chompret</surname><given-names>A</given-names></name><name><surname>Ellison</surname><given-names>JW</given-names></name><name><surname>Briere</surname><given-names>JJ</given-names></name><name><surname>Rustin</surname><given-names>P</given-names></name><name><surname>Gimenez-Roqueplo</surname><given-names>AP</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Carney</surname><given-names>JA</given-names></name><name><surname>Stratakis</surname><given-names>CA</given-names></name></person-group><article-title>Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD</article-title><source>Eur J Hum Genet</source><year>2008</year><volume>16</volume><fpage>79</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201904</pub-id><?supplied-pmid 17667967?><pub-id pub-id-type="pmid">17667967</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Smyrk</surname><given-names>TC</given-names></name><name><surname>Young</surname><given-names>WF</given-names><suffix>Jr</suffix></name><name><surname>Stratakis</surname><given-names>CA</given-names></name><name><surname>Carney</surname><given-names>JA</given-names></name></person-group><article-title>Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviourally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases</article-title><source>Am J Surg Pathol</source><year>2010</year><volume>34</volume><fpage>53</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e3181c20f4f</pub-id><?supplied-pmid 19935059?><pub-id pub-id-type="pmid">19935059</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajor</surname><given-names>J</given-names></name></person-group><article-title>Gastrointestinal stromal tumors in patients with type 1 neurofibromatosis</article-title><source>Clin Exp Med J</source><year>2009</year><volume>3</volume><fpage>247</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1556/CEMED.3.2009.28478</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agaram</surname><given-names>NP</given-names></name><name><surname>Wong</surname><given-names>GC</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Maki</surname><given-names>RG</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><name><surname>Dematteo</surname><given-names>RP</given-names></name><name><surname>Besmer</surname><given-names>P</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name></person-group><article-title>Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors</article-title><source>Genes Chromosomes Cancer</source><year>2008</year><volume>47</volume><fpage>853</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1002/gcc.20589</pub-id><?supplied-pmid 18615679?><pub-id pub-id-type="pmid">18615679</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hostein</surname><given-names>I</given-names></name><name><surname>Faur</surname><given-names>N</given-names></name><name><surname>Primois</surname><given-names>C</given-names></name><name><surname>Boury</surname><given-names>F</given-names></name><name><surname>Denard</surname><given-names>J</given-names></name><name><surname>Emile</surname><given-names>JF</given-names></name><name><surname>Bringuier</surname><given-names>PP</given-names></name><name><surname>Scoazec</surname><given-names>JY</given-names></name><name><surname>Coindre</surname><given-names>JM</given-names></name></person-group><article-title>BRAF mutation status in gastrointestinal stromal tumors</article-title><source>Am J Clin Pathol</source><year>2010</year><volume>133</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1309/AJCPPCKGA2QGBJ1R</pub-id><?supplied-pmid 20023270?><pub-id pub-id-type="pmid">20023270</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniels</surname><given-names>M</given-names></name><name><surname>Lurkin</surname><given-names>I</given-names></name><name><surname>Pauli</surname><given-names>R</given-names></name><name><surname>Erbst&#x000f6;sser</surname><given-names>E</given-names></name><name><surname>Hildebrandt</surname><given-names>U</given-names></name><name><surname>Hellwig</surname><given-names>K</given-names></name><name><surname>Zschille</surname><given-names>U</given-names></name><name><surname>L&#x000fc;ders</surname><given-names>P</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>G</given-names></name><name><surname>Knolle</surname><given-names>J</given-names></name><name><surname>Stengel</surname><given-names>B</given-names></name><name><surname>Prall</surname><given-names>F</given-names></name><name><surname>Hertel</surname><given-names>K</given-names></name><name><surname>Lobeck</surname><given-names>H</given-names></name><name><surname>Popp</surname><given-names>B</given-names></name><name><surname>Theissig</surname><given-names>F</given-names></name><name><surname>W&#x000fc;nsch</surname><given-names>P</given-names></name><name><surname>Zwarthoff</surname><given-names>E</given-names></name><name><surname>Agaimy</surname><given-names>A</given-names></name><name><surname>Schneider-Stock</surname><given-names>R</given-names></name></person-group><article-title>Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST)</article-title><source>Cancer Lett</source><year>2011</year><volume>312</volume><fpage>43</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2011.07.029</pub-id><?supplied-pmid 21906875?><pub-id pub-id-type="pmid">21906875</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pantaleo</surname><given-names>MA</given-names></name><name><surname>Nannin</surname><given-names>M</given-names></name><name><surname>Corless</surname><given-names>CL</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name></person-group><article-title>Q<italic>uadruple</italic> wild-type (WT) GIST: defining the subset of GISTs that lack abnormalities of KIT, PDGFRA, SDH, and the RAS signalling pathway</article-title><source>Cancer Med</source><year>2014</year></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pantaleo</surname><given-names>MA</given-names></name><name><surname>Astolfi</surname><given-names>A</given-names></name><name><surname>Nannini</surname><given-names>M</given-names></name><name><surname>Ceccarelli</surname><given-names>C</given-names></name><name><surname>Formica</surname><given-names>S</given-names></name><name><surname>Santini</surname><given-names>D</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Corless</surname><given-names>C</given-names></name><name><surname>Dei Tos</surname><given-names>AP</given-names></name><name><surname>Paterini</surname><given-names>P</given-names></name><name><surname>Catena</surname><given-names>F</given-names></name><name><surname>Maleddu</surname><given-names>A</given-names></name><name><surname>Saponara</surname><given-names>M</given-names></name><name><surname>Di Battista</surname><given-names>M</given-names></name><name><surname>Biasco</surname><given-names>G</given-names></name></person-group><article-title>Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours</article-title><source>Histopathology</source><year>2011</year><volume>59</volume><fpage>1071</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2559.2011.04071.x</pub-id><?supplied-pmid 22175887?><pub-id pub-id-type="pmid">22175887</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beadling</surname><given-names>C</given-names></name><name><surname>Patterson</surname><given-names>J</given-names></name><name><surname>Justusson</surname><given-names>E</given-names></name><name><surname>Nelson</surname><given-names>D</given-names></name><name><surname>Pantaleo</surname><given-names>MA</given-names></name><name><surname>Hornick</surname><given-names>JL</given-names></name><name><surname>Chac&#x000f3;n</surname><given-names>M</given-names></name><name><surname>Corless</surname><given-names>CL</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name></person-group><article-title>Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA</article-title><source>Cancer Med</source><year>2013</year><volume>2</volume><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/cam4.57</pub-id><?supplied-pmid 24133624?><pub-id pub-id-type="pmid">24133624</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muff</surname><given-names>R</given-names></name><name><surname>Born</surname><given-names>W</given-names></name><name><surname>Fischer</surname><given-names>JA</given-names></name></person-group><article-title>Calcitonin, calcitonin gene-related peptide, adrenomedullin and amylin: homologous peptides, separate receptors and overlapping biological actions</article-title><source>Eur J Endocrinol</source><year>1995</year><volume>133</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1530/eje.0.1330017</pub-id><?supplied-pmid 7627335?><pub-id pub-id-type="pmid">7627335</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagner</surname><given-names>S</given-names></name><name><surname>Stahl</surname><given-names>U</given-names></name><name><surname>Grimm</surname><given-names>T</given-names></name><name><surname>St&#x000fc;rzl</surname><given-names>M</given-names></name><name><surname>Lang</surname><given-names>RE</given-names></name></person-group><article-title>Expression of calcitonin receptor-like receptor in human vascular tumours</article-title><source>J Clin Pathol</source><year>2006</year><volume>59</volume><fpage>1104</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1136/jcp.2005.026930</pub-id><?supplied-pmid 17021138?><pub-id pub-id-type="pmid">17021138</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mennel</surname><given-names>HD</given-names></name><name><surname>Hallier-Neelsen</surname><given-names>M</given-names></name><name><surname>Hagner</surname><given-names>S</given-names></name><name><surname>Benes</surname><given-names>L</given-names></name></person-group><article-title>Two novel cell specific receptor proteins, CRLR and CD 117 in human glial tumors</article-title><source>Clin Neuropathol</source><year>2006</year><volume>25</volume><fpage>107</fpage><lpage>114</lpage><?supplied-pmid 16719406?><pub-id pub-id-type="pmid">16719406</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benes</surname><given-names>L</given-names></name><name><surname>Kappus</surname><given-names>C</given-names></name><name><surname>McGregor</surname><given-names>GP</given-names></name><name><surname>Bertalanffy</surname><given-names>H</given-names></name><name><surname>Mennel</surname><given-names>HD</given-names></name><name><surname>Hagner</surname><given-names>S</given-names></name></person-group><article-title>The immunohistochemical expression of calcitonin receptor-like receptor (CRLR) in human gliomas</article-title><source>J Clin Pathol</source><year>2004</year><volume>57</volume><fpage>172</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1136/jcp.2003.12997</pub-id><?supplied-pmid 14747444?><pub-id pub-id-type="pmid">14747444</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>M</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>U</given-names></name><name><surname>Ashwodt</surname><given-names>T</given-names></name><name><surname>Keene</surname><given-names>DR</given-names></name><name><surname>Brunken</surname><given-names>WJ</given-names></name><name><surname>Burgeson</surname><given-names>RE</given-names></name><name><surname>Bruckner</surname><given-names>P</given-names></name><name><surname>Bruckner-Tuderman</surname><given-names>L</given-names></name></person-group><article-title>A novel marker of tissue junctions, collagen XXII</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>22514</fpage><lpage>22521</lpage><pub-id pub-id-type="doi">10.1074/jbc.M400536200</pub-id><?supplied-pmid 15016833?><pub-id pub-id-type="pmid">15016833</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>ES</given-names></name><name><surname>Rao</surname><given-names>VN</given-names></name><name><surname>Papas</surname><given-names>TS</given-names></name></person-group><article-title>The erg gene: a human gene related to the ets oncogene</article-title><source>Proc Natl Acad Sci U S A</source><year>1987</year><volume>84</volume><fpage>6131</fpage><lpage>6135</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.17.6131</pub-id><?supplied-pmid 3476934?><pub-id pub-id-type="pmid">3476934</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>AH</given-names></name><name><surname>Corrick</surname><given-names>CM</given-names></name><name><surname>Tymms</surname><given-names>MJ</given-names></name><name><surname>Hertzog</surname><given-names>PJ</given-names></name><name><surname>Kola</surname><given-names>I</given-names></name></person-group><article-title>Human ERG is a proto-oncogene with mitogenic and transforming activity</article-title><source>Oncogene</source><year>1995</year><volume>10</volume><fpage>1423</fpage><lpage>1430</lpage><?supplied-pmid 7731694?><pub-id pub-id-type="pmid">7731694</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>PH</given-names></name><name><surname>Lessnick</surname><given-names>SL</given-names></name><name><surname>Lopez-Terrada</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>XF</given-names></name><name><surname>Triche</surname><given-names>TJ</given-names></name><name><surname>Denny</surname><given-names>CT</given-names></name></person-group><article-title>A second Ewing&#x02019;s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG</article-title><source>Nat Genet</source><year>1994</year><volume>6</volume><fpage>146</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/ng0294-146</pub-id><?supplied-pmid 8162068?><pub-id pub-id-type="pmid">8162068</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>PH</given-names></name><name><surname>Lessnick</surname><given-names>SL</given-names></name><name><surname>Lopez-Terrada</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>XF</given-names></name><name><surname>Triche</surname><given-names>TJ</given-names></name><name><surname>Denny</surname><given-names>CT</given-names></name></person-group><article-title>Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer</article-title><source>Science</source><year>2005</year><volume>310</volume><fpage>644</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1126/science.1117679</pub-id><pub-id pub-id-type="pmid">16254181</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>JH</given-names></name></person-group><article-title>Acute myeloid leukemia: a central role for the ETS factor ERG</article-title><source>Int J Biochem Cell Biol</source><year>2011</year><volume>43</volume><fpage>1413</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2011.05.014</pub-id><?supplied-pmid 21664289?><pub-id pub-id-type="pmid">21664289</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>ZF</given-names></name><name><surname>Paetau</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>SH</given-names></name><name><surname>Dobi</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Sesterhenn</surname><given-names>I</given-names></name></person-group><article-title>ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma</article-title><source>Am J Surg Pathol</source><year>2011</year><volume>35</volume><fpage>432</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e318206b67b</pub-id><?supplied-pmid 21317715?><pub-id pub-id-type="pmid">21317715</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Patel</surname><given-names>NR</given-names></name><name><surname>Caragea</surname><given-names>M</given-names></name><name><surname>Hogendoorn</surname><given-names>PC</given-names></name><name><surname>L&#x000f3;pez-Terrada</surname><given-names>D</given-names></name><name><surname>Hornick</surname><given-names>JL</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name></person-group><article-title>Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma</article-title><source>Mod Pathol</source><year>2012</year><volume>25</volume><fpage>1378</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2012.97</pub-id><?supplied-pmid 22766791?><pub-id pub-id-type="pmid">22766791</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Sarlomo-Rikala</surname><given-names>M</given-names></name><name><surname>Abdullaev</surname><given-names>Z</given-names></name><name><surname>Pack</surname><given-names>SD</given-names></name><name><surname>Fetsch</surname><given-names>JF</given-names></name></person-group><article-title>ERG expression in epithelioid sarcoma: a diagnostic pitfall</article-title><source>Am J Surg Pathol</source><year>2013</year><volume>37</volume><fpage>1580</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e31828de23a</pub-id><?supplied-pmid 23774169?><pub-id pub-id-type="pmid">23774169</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiele</surname><given-names>CJ</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>McKee</surname><given-names>AE</given-names></name></person-group><article-title>On Trk&#x02013;the TrkB signal transduction pathway is an increasingly important target in cancer biology</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>5962</fpage><lpage>5967</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0651</pub-id><?supplied-pmid 19755385?><pub-id pub-id-type="pmid">19755385</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodeur</surname><given-names>GM</given-names></name><name><surname>Nakagawara</surname><given-names>A</given-names></name><name><surname>Yamashiro</surname><given-names>DJ</given-names></name><name><surname>Ikegaki</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>XG</given-names></name><name><surname>Azar</surname><given-names>CG</given-names></name><name><surname>Lee</surname><given-names>CP</given-names></name><name><surname>Evans</surname><given-names>AE</given-names></name></person-group><article-title>Expression of TrkA, TrkB and TrkC in human neuroblastomas</article-title><source>J Neurooncol</source><year>1997</year><volume>31</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1023/A:1005729329526</pub-id><?supplied-pmid 9049830?><pub-id pub-id-type="pmid">9049830</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGregor</surname><given-names>LM</given-names></name><name><surname>McCune</surname><given-names>BK</given-names></name><name><surname>Graff</surname><given-names>JR</given-names></name><name><surname>McDowell</surname><given-names>PR</given-names></name><name><surname>Romans</surname><given-names>KE</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Ball</surname><given-names>DW</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name><name><surname>Nelkin</surname><given-names>BD</given-names></name></person-group><article-title>Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>4540</fpage><lpage>4545</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.8.4540</pub-id><?supplied-pmid 10200298?><pub-id pub-id-type="pmid">10200298</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>F</given-names></name><name><surname>Mimata</surname><given-names>H</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Sakamoto</surname><given-names>S</given-names></name><name><surname>Hamada</surname><given-names>Y</given-names></name><name><surname>Nomura</surname><given-names>Y</given-names></name></person-group><article-title>Autocrine expression of neurotrophins and their receptors in prostate cancer</article-title><source>Int J Urol</source><year>2001</year><volume>8</volume><fpage>S28</fpage><lpage>S34</lpage><pub-id pub-id-type="doi">10.1046/j.1442-2042.2001.00331.x</pub-id><?supplied-pmid 11442674?><pub-id pub-id-type="pmid">11442674</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name><name><surname>Takeshita</surname><given-names>M</given-names></name><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Yano</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name></person-group><article-title>Role and relevance of TrkB mutations and expression in non-small cell lung cancer</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>2638</fpage><lpage>2645</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-3034</pub-id><?supplied-pmid 21242122?><pub-id pub-id-type="pmid">21242122</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupferman</surname><given-names>ME</given-names></name><name><surname>Jiffar</surname><given-names>T</given-names></name><name><surname>El-Naggar</surname><given-names>A</given-names></name><name><surname>Yilmaz</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Xie</surname><given-names>T</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Holsinger</surname><given-names>FC</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Myers</surname><given-names>JN</given-names></name></person-group><article-title>TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>2047</fpage><lpage>2059</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.486</pub-id><?supplied-pmid 20101235?><pub-id pub-id-type="pmid">20101235</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sclabas</surname><given-names>GM</given-names></name><name><surname>Fujioka</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Frederick</surname><given-names>WA</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Yokoi</surname><given-names>K</given-names></name><name><surname>Evans</surname><given-names>DB</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Fidler</surname><given-names>IJ</given-names></name><name><surname>Chiao</surname><given-names>PJ</given-names></name></person-group><article-title>Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>440</fpage><lpage>449</lpage><?supplied-pmid 15701826?><pub-id pub-id-type="pmid">15701826</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camoratto</surname><given-names>AM</given-names></name><name><surname>Jani</surname><given-names>JP</given-names></name><name><surname>Angeles</surname><given-names>TS</given-names></name><name><surname>Maroney</surname><given-names>AC</given-names></name><name><surname>Sanders</surname><given-names>CY</given-names></name><name><surname>Murakata</surname><given-names>C</given-names></name><name><surname>Neff</surname><given-names>NT</given-names></name><name><surname>Vaught</surname><given-names>JL</given-names></name><name><surname>Isaacs</surname><given-names>JT</given-names></name><name><surname>Dionne</surname><given-names>CA</given-names></name></person-group><article-title>CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity</article-title><source>Int J Cancer</source><year>1997</year><volume>72</volume><fpage>673</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19970807)72:4&#x0003c;673::AID-IJC20&#x0003e;3.0.CO;2-B</pub-id><?supplied-pmid 9259409?><pub-id pub-id-type="pmid">9259409</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miknyoczki</surname><given-names>SJ</given-names></name><name><surname>Dionne</surname><given-names>CA</given-names></name><name><surname>Klein-Szanto</surname><given-names>AJ</given-names></name><name><surname>Ruggeri</surname><given-names>BA</given-names></name></person-group><article-title>The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness</article-title><source>Ann N YAcad Sci</source><year>1999</year><volume>880</volume><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb09530.x</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>AE</given-names></name><name><surname>Kisselbach</surname><given-names>KD</given-names></name><name><surname>Yamashiro</surname><given-names>DJ</given-names></name><name><surname>Ikegaki</surname><given-names>N</given-names></name><name><surname>Camoratto</surname><given-names>AM</given-names></name><name><surname>Dionne</surname><given-names>CA</given-names></name><name><surname>Brodeur</surname><given-names>GM</given-names></name></person-group><article-title>Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts</article-title><source>Clin Cancer Res</source><year>1999</year><volume>5</volume><fpage>3594</fpage><lpage>3602</lpage><?supplied-pmid 10589776?><pub-id pub-id-type="pmid">10589776</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strock</surname><given-names>CJ</given-names></name><name><surname>Park</surname><given-names>JI</given-names></name><name><surname>Rosen</surname><given-names>M</given-names></name><name><surname>Dionne</surname><given-names>C</given-names></name><name><surname>Ruggeri</surname><given-names>B</given-names></name><name><surname>Jones-Bolin</surname><given-names>S</given-names></name><name><surname>Denmeade</surname><given-names>SR</given-names></name><name><surname>Ball</surname><given-names>DW</given-names></name><name><surname>Nelkin</surname><given-names>BD</given-names></name></person-group><article-title>CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>5559</fpage><lpage>5563</lpage><?supplied-pmid 14500395?><pub-id pub-id-type="pmid">14500395</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>JL</given-names></name><name><surname>Kindler</surname><given-names>H</given-names></name><name><surname>Deeken</surname><given-names>J</given-names></name><name><surname>Bhargava</surname><given-names>P</given-names></name><name><surname>Vogelzang</surname><given-names>NJ</given-names></name><name><surname>Rizvi</surname><given-names>N</given-names></name><name><surname>Luhtala</surname><given-names>T</given-names></name><name><surname>Boylan</surname><given-names>S</given-names></name><name><surname>Dordal</surname><given-names>M</given-names></name><name><surname>Robertson</surname><given-names>P</given-names></name><name><surname>Hawkins</surname><given-names>MJ</given-names></name><name><surname>Ratain</surname><given-names>MJ</given-names></name></person-group><article-title>Phase I trial of orallyadministeredCEP-701, anovelneurotrophin receptor-linked tyrosine kinase inhibitor</article-title><source>Invest New Drugs</source><year>2005</year><volume>23</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1023/B:DRUG.0000047103.64335.b0</pub-id><?supplied-pmid 15528978?><pub-id pub-id-type="pmid">15528978</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Lamb</surname><given-names>ML</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Block</surname><given-names>MH</given-names></name><name><surname>Lyne</surname><given-names>PD</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Davies</surname><given-names>AM</given-names></name><name><surname>Zhang</surname><given-names>HJ</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Mohr</surname><given-names>PJ</given-names></name><name><surname>Kaus</surname><given-names>RJ</given-names></name><name><surname>Josey</surname><given-names>JA</given-names></name><name><surname>Hoffmann</surname><given-names>E</given-names></name><name><surname>Thress</surname><given-names>K</given-names></name><name><surname>Macintyre</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Omer</surname><given-names>CA</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name></person-group><article-title>Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases</article-title><source>J Med Chem</source><year>2008</year><volume>51</volume><fpage>4672</fpage><lpage>4684</lpage><pub-id pub-id-type="doi">10.1021/jm800343j</pub-id><?supplied-pmid 18646745?><pub-id pub-id-type="pmid">18646745</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Mulkerin</surname><given-names>D</given-names></name><name><surname>Rothenberg</surname><given-names>M</given-names></name><name><surname>Holen</surname><given-names>KD</given-names></name><name><surname>Lockhart</surname><given-names>AC</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Berlin</surname><given-names>J</given-names></name></person-group><article-title>A phase I trial of CEP-701&#x02009;+&#x02009;gemcitabine in patients with advanced adenocarcinoma of the pancreas</article-title><source>Invest New Drugs</source><year>2008</year><volume>26</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1007/s10637-008-9118-3</pub-id><?supplied-pmid 18217204?><pub-id pub-id-type="pmid">18217204</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Wongvipat</surname><given-names>J</given-names></name><name><surname>Shamu</surname><given-names>T</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name><name><surname>Dewell</surname><given-names>S</given-names></name><name><surname>Maki</surname><given-names>RG</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><article-title>ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours</article-title><source>Nature</source><year>2010</year><volume>467</volume><fpage>849</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1038/nature09409</pub-id><?supplied-pmid 20927104?><pub-id pub-id-type="pmid">20927104</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nannini</surname><given-names>M</given-names></name><name><surname>Biasco</surname><given-names>G</given-names></name><name><surname>Astolfi</surname><given-names>A</given-names></name><name><surname>Pantaleo</surname><given-names>MA</given-names></name></person-group><article-title>An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST)</article-title><source>J Med Genet</source><year>2013</year><volume>50</volume><fpage>653</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2013-101695</pub-id><?supplied-pmid 23833252?><pub-id pub-id-type="pmid">23833252</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>TopHat: discovering splice junctions with RNA-Seq</article-title><source>Bioinformatics</source><year>2009</year><volume>9</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp120</pub-id><pub-id pub-id-type="pmid">19289445</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Handsaker</surname><given-names>B</given-names></name><name><surname>Wysoker</surname><given-names>A</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Homer</surname><given-names>N</given-names></name><name><surname>Marth</surname><given-names>G</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><collab>1000 Genome Project Data Processing Subgroup</collab></person-group><article-title>The Sequence Alignment/Map format and SAMtools</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>2078</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp352</pub-id><?supplied-pmid 19505943?><pub-id pub-id-type="pmid">19505943</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anders</surname><given-names>S</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>Differential expression analysis for sequence count data</article-title><source>Genome Biol</source><year>2010</year><volume>11</volume><fpage>R106</fpage><pub-id pub-id-type="doi">10.1186/gb-2010-11-10-r106</pub-id><?supplied-pmid 20979621?><pub-id pub-id-type="pmid">20979621</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><?supplied-pmid 19910308?><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR65"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/685/prepub">http://www.biomedcentral.com/1471-2407/14/685/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>